BOSSI MARIO

Ruolo: 
Tecnico - amministrativo
Telefono: 
0264488117
Stanza: 
U8, Piano: I, Stanza: L 1.15
Via Cadore, 48 - 20900 MONZA

Pubblicazioni

  • De Marco, S., Torsello, B., Minutiello, E., Bossi, M., Bombelli, S., Grasselli, C., et al. (2021). Abl2 knockdown affects TGFb-mediated 3D invasion of ccRCC cells. Intervento presentato a: AMP Europe 2020, Milano. Dettaglio
  • Torsello, B., De Marco, S., Bossi, M., Bombelli, S., Grasselli, C., Zucchini, N., et al. (2021). Abl2 is required for TGFb1-induced invasion of clear cell Renal Cell Carcinoma cells. Intervento presentato a: EACR 2021 Virtual Congress, Torino. Dettaglio
  • Barbone, G., Bravin, A., Mittone, A., Kraiger, M., Hrabe de Angelis, M., Bossi, M., et al. (2020). Establishing sample-preparation protocols for X-ray phase-contrast CT of rodent spinal cords: Aldehyde fixations and osmium impregnation. JOURNAL OF NEUROSCIENCE METHODS, 339. Dettaglio
  • Fontana, D., Mauri, M., Renso, R., Docci, M., Crespiatico, I., Rost, L., et al. (2020). ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine. BLOOD, 136(Supplement_2), LBA-5-LBA-5 [10.1182/BLOOD-2020-143852]. Dettaglio
  • Fontana, D., Mauri, M., Renso, R., Docci, M., Crespiatico, I., Rost, L., et al. (2020). ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. NATURE COMMUNICATIONS, 11(1) [10.1038/s41467-020-19721-w]. Dettaglio